CD9 and myeloid sarcoma: Moreover, our MS and non-MS pathological samples displayed a significantly lower enrichment of CD63+ EVs in CSF and CD81+ EVs in serum, and a higher percentage of double-positive CD81+/CD9+ EVs in CSF and CD63+/CD9+ in serum.